Prospects for Improving Brain Function in Individuals with Down Syndrome

@article{Costa2013ProspectsFI,
  title={Prospects for Improving Brain Function in Individuals with Down Syndrome},
  author={A. Costa and J. J. Scott-McKean},
  journal={CNS Drugs},
  year={2013},
  volume={27},
  pages={679-702}
}
  • A. Costa, J. J. Scott-McKean
  • Published 2013
  • Psychology, Medicine
  • CNS Drugs
  • Down syndrome (DS), which results from an extra copy of chromosome 21 (trisomy 21), is the most common genetically defined cause of intellectual disability. Although no pharmacotherapy aimed at counteracting the cognitive and adaptive deficits associated with this genetic disorder has been approved at present, there have been several new promising studies on pharmacological agents capable of rescuing learning/memory deficits seen in mouse models of DS. Here, we will review the available mouse… CONTINUE READING
    54 Citations

    Paper Mentions

    Interventional Clinical Trial
    The purpose of this research study is to learn if the medication Memantine Hydrochloride (the study medication) can help adolescents and young adults with Down syndrome. Dr. Alberto… Expand
    ConditionsDown Syndrome, Intellectual Disability
    InterventionDrug
    Timing of therapies for Down syndrome: the sooner, the better
    • 57
    • PDF
    Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice
    • 30
    Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome
    • 3
    • PDF

    References

    SHOWING 1-10 OF 218 REFERENCES
    On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome
    • A. Costa
    • Psychology, Medicine
    • Developmental Neuroscience
    • 2011
    • 40
    Synaptic and cognitive abnormalities in mouse models of down syndrome: Exploring genotype‐phenotype relationships
    • 172
    • Highly Influential
    Rescue of Synaptic Failure and Alleviation of Learning and Memory Impairments in a Trisomic Mouse Model of Down Syndrome
    • 28
    • Highly Influential
    • PDF
    Function and regulation of Dyrk1A: towards understanding Down syndrome
    • 145
    Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome
    • 158
    • PDF
    The neurobiologie consequences of down syndrome
    • 235
    Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial
    • 67
    • PDF
    Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model
    • 110